Table 1.
Characteristics of COVID-19 patients and control subjects.
| Characteristicsa | Control (n = 8) | Covid-19 (n = 9) |
|---|---|---|
| Age, years | 52.6 (47–60) | 61 (33–79) |
| Sex, male | 8 (100%) | 6 (66.7%) |
| Respiratory support | ||
| Oxygen supplementation | 0 (0%) | 3 (33.3%) |
| Mechanical ventilation | 0 (0%) | 6 (66.7%) |
| SAPS 3 | 59.25 (31–75) | |
| PaO2/FiO2 ratio | – | 210.75 (87–509.5) |
| Vasopressor | – | 3 (33.3%) |
| Time from symptom onset to blood sample, days | – | 10 (6–18) |
| Status on Jun 30th | ||
| Dead | – | 5 (55.55%) |
| Discharged | – | 1 (11.1%) |
| Hospitalized | – | 3 (33.3%) |
| Comorbidities | ||
| Obesity | 1 (11.1%) | 1 (11.1%) |
| Hypertension | 3 (33.3%) | 3 (33.3%) |
| Diabetes | 0 (0%) | 0 (0%) |
| Cancer | 0 (0%) | 0 (0%) |
| Chronic heart diseaseb | 0 (0%) | 0 (0%) |
| Presenting symptoms | ||
| Cough | 0 (0%) | 3 (33,3%) |
| Fever | 0 (0%) | 3 (33,3%) |
| Dyspnea | 0 (0%) | 4 (44,4%) |
| Headache | 0 (0%) | 0 (0%) |
| Anosmia | 0 (0%) | 0 (0%) |
| Laboratory findings on admission | ||
| Lymphocyte count, cells/mm3 | – | 1355.8 (552–2564) |
| Platelet count, ×1000/mm3 | – | 169.6 (92–278) |
| Leukocytes | – | 8036 (8.03–18,670) |
| C reactive protein, mg/L | – | 14.78 (0.1–30.8) |
aNumerical variables are represented as the median and the max range, and qualitative variables are represented as the number and the percentage.
bCoronary artery disease or congestive heart failure